Walleye Capital’s Elicio Therapeutics ELTX Stock Holding History

Walleye Capital’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,413	Closed	-$41K	–	2366
2021 Q4	$41K	Buy	+1,413	New	+$71.5K	﹤0.01%	1802

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's ELTX Position: Q1 2022 in Review

Walleye Capital sold out of Elicio Therapeutics (ELTX) in Q1 2022, closing a stake of 1,413 shares — an estimated $41K sold.

Walleye Capital first reported a position in ELTX in Q4 2021 and held it in 1 quarter. The position peaked at $41K in Q4 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

Walleye Capital reported no remaining Elicio Therapeutics position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 1,413 Elicio Therapeutics shares in Q1 2022, an estimated $41K.
Walleye Capital first reported a position in Elicio Therapeutics in Q4 2021 and held it in 1 quarter.
Walleye Capital's Elicio Therapeutics position peaked at $41K in Q4 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.